Evaluation of the OARSI and OMERACT-OARSI set of responder criteria in patients treated with Hylan G-F 20 for knee osteoarthritis.

被引：0
|
作者：
Bell, MJ
Bellamy, N
Goldsmith, CH
Tugwell, P
Torrance, GW
Raynauld, JP
Polisson, R
Pericak, D
Walker, V
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Univ Queensland, St Lucia, Qld 4067, Australia
[3] McMaster Univ, Hamilton, ON, Canada
[4] Univ Ottawa, Ottawa, ON, Canada
[5] Univ Montreal, Montreal, PQ, Canada
[6] Genzyme Corp, Cambridge, MA USA
[7] Innovus Res Inc, Burlington, ON, Canada
来源：
ARTHRITIS AND RHEUMATISM | 2003年 / 48卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1214
引用
收藏
页码：S482 / S482
页数：1
相关论文
共 50 条
  • [21] A prospective randomized health outcomes trial of hylan G-F 20 in the treatment of patients with knee osteoarthritis.
    Raynauld, JP
    Bellamy, N
    Goldsmith, C
    Tugwell, P
    Torrance, G
    Walker, V
    Schultz, M
    Pericak, D
    Band, P
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S340 - S340
  • [22] Predictors of osteoarthritis (OA) improvement in patients treated with hylan G-F 20 for knee OA
    Goldsmith, CH
    Bellamy, N
    Pericak, D
    Torrance, GW
    Raynauld, JP
    Bell, M
    Polisson, R
    OSTEOARTHRITIS AND CARTILAGE, 2004, 12 : S77 - S77
  • [23] Patient acceptable symptom state and OMERACT-OARSI set of responder criteria in joint replacement. Identification of cut-off values
    Escobar, A.
    Gonzalez, M.
    Quintana, J. M.
    Vrotsou, K.
    Bilbao, A.
    Herrera-Espineira, C.
    Garcia-Perez, L.
    Aizpuru, F.
    Sarasqueta, C.
    OSTEOARTHRITIS AND CARTILAGE, 2012, 20 (02) : 87 - 92
  • [24] Viscosupplementation for knee osteoarthritis: a focus on Hylan G-F 20
    Webb, David
    Naidoo, Poobalan
    ORTHOPEDIC RESEARCH AND REVIEWS, 2018, 10 : 73 - 81
  • [25] Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017
    Smith, Toby O.
    Mansfield, Michael
    Hawker, Gillian A.
    Hunter, David J.
    March, Lyn M.
    Boers, Maarten
    Shea, Beverley J.
    Christensen, Robin
    Guillemin, Francis
    Terwee, Caroline B.
    Williamson, Paula R.
    Roos, Ewa M.
    Loeser, Richard F.
    Schnitzer, Thomas J.
    Kloppenburg, Margreet
    Neogi, Tuhina
    Ladel, Christoph H.
    Kalsi, Gurdyal
    Kaiser, Ulrike
    Buttel, Thomas W.
    Ashford, Anne E.
    Mobasheri, Ali
    Ardene, Nigel K.
    Tennant, Alan
    Hochberg, Marc C.
    de Witel, Maarten
    Tugwell, Peter
    Conaghan, Philip G.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (08) : 976 - 980
  • [26] Comparing different therapeutic classes for the treatment of osteoarthritis of the knee: data from the OMERACT-OARSI responder criteria analysis - Reply to letter to the editor - Answer to Philip A. Band
    Dougados, M
    OSTEOARTHRITIS AND CARTILAGE, 2005, 13 (05) : 450 - 450
  • [27] A Randomized Controlled Trial of Hylan G-F 20 for the Treatment of Carpometacarpal Osteoarthritis.
    Mandl, Lisa A.
    Wolfe, Scott
    Daluiski, Aaron
    Hotchkiss, Robert N.
    Lyman, Stephen L.
    Katz, Jeffrey N.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S475 - S476
  • [28] HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS (OA): A COCHRANE REVIEW
    Bellamy, N., Jr.
    Campbell, J.
    Gee, T.
    Robinson, V.
    Wells, G.
    Bourne, R.
    RHEUMATOLOGY, 2004, 43 : 63 - 64
  • [29] Womac 20,50,70 response levels in patients treated with hylan G-F 20 for knee osteoarthritis
    Bellamy, N
    Bell, MJ
    Goldsmith, CH
    Torrance, GW
    Raynauld, J
    Tugwell, P
    Polisson, R
    Pericak, D
    Walker, V
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 359 - 359
  • [30] Intrarticular Hylan G-F 20 (Synvisc)® in the treatment of patients with osteoarthritis of the knee.
    Sharlati, J
    Hatef, M
    Jokar, M
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 3 - 3
12345